The AI Renal & Nephrology Research Intelligence agent — nephron to outcome.
A scientific research agent (not a chatbot, not a diagnostic tool) that discovers, connects, analyses, challenges and synthesises kidney-disease knowledge from authorized literature, databases, datasets and enterprise tools — to help you understand what is known, what is unknown, what may be true, what has failed and what to test next.
Twelve deeply-connected knowledge domains spanning the research lifecycle.
Chronic kidney disease, diabetic & hypertensive nephropathy, glomerular diseases (IgAN, FSGS, membranous), polycystic kidney disease, AKI and cardio-renal-metabolic overlap.
Nephron & podocyte biology, glomerular filtration, tubular transport, the renin–angiotensin system, mineral & electrolyte handling, and kidney–heart–metabolism crosstalk.
Tubulointerstitial fibrosis, inflammation, hypoxia, complement activation and the mechanisms driving irreversible nephron loss — mechanism → biomarker → target → therapy → outcome.
Genomics (APOL1, rare variants, PRS), single-cell & spatial kidney atlases, urinary & plasma proteomics and metabolomics — connected gene → cell → nephron → phenotype.
Human-genetic, functional and multi-omics evidence for renal targets — with tractability, kidney exposure, safety and prior program failures clearly separated.
SGLT2 inhibitors, MRAs, endothelin & complement inhibitors, RNA therapeutics and repurposing — across the discovery-to-development cascade, including cardio-renal combinations.
eGFR, albuminuria/UACR, novel injury biomarkers (KIM-1, NGAL), and progression/response signatures — with performance, validation and clinical-utility context.
Design, population, endpoints (eGFR slope, ESKD, doubling of creatinine), surrogate acceptance, comparators, results and adverse events — surfacing failed hypotheses and design opportunities.
Renal replacement therapy, transplant immunology & rejection, anemia & mineral-bone disease management, and real-world effectiveness — signal vs confirmed causality.
eGFR-slope & survival modelling, competing-risks analysis, causal inference and multi-omics integration on authorized nephrology datasets.
Reasons across Disease ↔ Gene ↔ Cell ↔ Pathway ↔ Biomarker ↔ Target ↔ Drug ↔ Trial ↔ Outcome, with every claim traceable to primary sources.
Finds conflicting findings, unexplained progression mechanisms, missing biomarkers and poorly-validated targets — then frames testable hypotheses and experiments.
Surface novel, testable research directions and drug-repurposing leads across the whole ecosystem — not a single paper.
Integrate literature, omics, trials and real-world data into one traceable evidence graph so hidden connections become visible.
A built-in scientific critic tests for confounding, batch effects, power, publication bias, replication and prior failures.
Research questions, proposals, protocols, SAPs, reviews and manuscript scaffolds — never fabricating data, patients, stats or citations.
Statements are tagged so you always know their standing — and confidence is stated, never inflated. Citations, DOIs, PMIDs, dataset and trial IDs are drawn from primary sources; if a source can't be verified it says so. Nephrology Genius is a research-intelligence system, not a substitute for a physician — it does not diagnose or treat individuals.
We use cookies to run Anxya Health and improve your experience. Choose how we may use them. Read our Cookie Policy, Privacy Policy and Terms.